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ABSTRACT 
Title of the Abstract:  
Evaluation of predictors for choledocholithiasis (common bile duct stones) and 
assessment of outcomes after treatment 
Department: Department of General Surgery, Christian Medical College, Vellore 
Name of the candidate: Dr. Sam Joel M. 
Degree and Subject: Master of Surgery – General Surgery 
Name of the Guide: Dr. Philip Joseph 
Objectives: 
1. To study the clinical, laboratory and radiological findings of patients diagnosed 
with common bile duct stones. 
2. To study the current practice of managing this condition in our tertiary care 
hospital (Christian Medical College and Hospital).   
3. To obtain data of a one year follow up of these patients who had undergone 
treatment for choledocholithiasis.  
Background:  
Common bile duct (CBD) stones are seen in 5% to 10% of those undergoing 
cholecystectomy.  Missed CBD stones pose a risk of recurrent symptoms of 
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abdominal pain, pancreatitis, and cholangitis unless identified at presentation. 
Therefore identifying the key predictors at presentation is of great value.  
 Methods: 
Cohort of patients diagnosed with choledocholithiasis who presented to the 
outpatient clinic of Hepatic Pancreatic and Biliary Surgery, General Surgery and 
Gastroenterology departments at Christian Medical College, Vellore from July 
2008 to June 2012 were included in the study, and one year follow up data was 
also collected. The presenting history, clinical examination, laboratory tests and 
radiological imaging in the patients were recorded in the performa. 
Results:  
The management practice in this tertiary care centre along with the various 
relevant clinical, biochemical and imaging parameters were identified. Abdominal 
pain was the common complaint (76%). Jaundice was a significant predictor for 
failure of ERCP. Abdominal ultrasonography commonly showed CBD dilation 
(85.4%) and intrahepatic biliary radical dilatation. MRI was the most sensitive to 
demonstrate CBD stone (86.6%). ERCP was the primary modality of treatment.  
CBD exploration was the treatment of choice in case of failed ERCP and stone 
extraction. There were recurrent CBD stones in 5% of the follow-up population. 
Discussion: 
The most common clinical presentation of choledocholithiasis was abdominal pain. 
The presence of a dilated common bile duct of above 10mm associated with 
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intrahepatic biliary dilatation was the commonest initial radiological finding. 
Abdominal ultrasound was an effective modality to pick up common bile duct 
stones but MRI had the best sensitivity. ERCP appeared to be the effective and 
preferred primary intervention of choice with failure rates being more in those 
having jaundice and dilated bile ducts. Delay in laparoscopic cholecystectomy 
following ERCP lead to a higher conversion rate to an open procedure. Serum 
alkaline phosphatase appeared to the best marker on follow up. 
Keywords: common bile duct stone, common bile duct exploration, endoscopic 
retrograde cholangiopancreatography (ERCP).  
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Chapter 1 
INTRODUCTION 
Choledocholithiasis refers to the presence of stones in the common bile duct. 
It is a major health problem worldwide, particularly in the adult population. 
Autopsies of ancient Chinese and Egyptian mummies had revealed the 
existence of gallstones for at least 3500 years. The common bile duct stones 
are mostly secondary in origin and thought to have migrated from the 
primary site of origin in the gallbladder through the cystic duct. It is 
suspected in patients with symptomatic cholelithiasis, cholangitis and acute 
biliary pancreatitis. Primary choledocholithiasis is less common. Early 
identification of patients who are likely to have choledocholithiasis is 
essential since missed common bile duct stones can increase the risk of 
recurrent symptoms and life threatening complications like pancreatitis and 
ascending cholangitis. 
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Chapter 2 
AIM 
Evaluation of predictors for choledocholithiasis (common bile duct stones) 
and assessment of outcomes after treatment.  
 
 
OBJECTIVES 
1. To study the clinical, laboratory and radiological findings of patients 
diagnosed with common bile duct stones. 
2. To study the current practice of managing this condition in our tertiary care 
hospital (Christian Medical College and Hospital).  
3. To obtain data of a one year follow up of these patients who had 
undergone treatment for choledocholithiasis. 
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Chapter 3 
REVIEW OF LITERATURE 
3.1.0. Background 
Gall stone disease is one of the most common and major health problem that 
requires hospital admission, particularly in the Western adult population (1). 
According to the National Health And Nutrition Examination  Survey 
(NHANES III ), over 20 million Americans are estimated to have gallstone 
disease (2). The prevalence of this disease shows ethnic variability and 
ranges from  10% to 15% in United States and Europe (3). 
There is wide difference in prevalence of gall stones in India, with 2 to 4 fold 
higher prevalence in North Indians than the Southern population.  Among the 
North Indians it was more prevalent in the Bengali community (4). 
The clinical spectrum of this disease ranges from an asymptomatic state to 
fatal complications. Patients with asymptomatic disease have an annual risk 
of 1% for biliary colic (5), 0.3% for acute cholecystitis (6), 0.2% for 
symptomatic choledocholithiasis (7) and up to 1.5% for gall stone 
pancreatitis in 20 to 30 years (8),(9). 
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The patients presenting with symptomatic gall stones carry a risk of  5% to 
12%  for bile duct stones (10) and these are found in 18% to 33% of patients 
with acute biliary pancreatitis (11).  
The primary bile duct stones are more prevalent in the Asian population. It 
can be either formed either intrahepatic or extrahepatic bile duct. These are 
usually brown pigment stone which are formed due to bacterial colonisation 
of bile and bile stasis (12),(13). 
The secondary bile duct stones are due to the passage of gall bladder stones 
into the common bile duct. These are more common in the Western world 
and the elderly. They also occur frequently in those who had chronic 
inflammation of the common bile duct due to sclerosing cholangitis or 
parasitic infestation (14). 
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 3.2.0. Overview of biliary anatomy 
The anatomy of the biliary tree is variable and at times very complex, thus 
posing great challenges for diagnosis and treatment. A thorough knowledge 
of this complex anatomy and its variations is essential in radiologic, 
endoscopic, and surgical approaches to the biliary system. 
3.2.1 Embryological development 
The liver and the biliary system originate from the embryonic foregut. At 
four weeks a diverticulum arises from the ventral surface of the foregut. This 
liver diverticulum initially separates into a caudal and cranial portion, the 
caudal portion gives rise to the cystic duct and gallbladder and the cranial 
portion gives rise to the intrahepatic and hilar bile ducts. The ductal cells 
follow the development of the connective tissues around the portal vein 
branches. At first, the bile duct precursors are discontinuous but eventually 
they join one another and then connect with the extrahepatic bile ducts. 
The extrahepatic biliary system is initially occluded with epithelial cells but 
later it canalizes as cells degenerate. The stalk that connects the hepatic and 
cystic ducts to the duodenum differentiates into the common bile duct (CBD). 
Initially the duct is attached to the ventral aspect of the duodenum but when 
the duodenum undergoes rotation later on in development, there is 
repositioning of the CBD to the dorsal aspect of the duodenal wall (15). 
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Fig.1 : The liver bud begins to expand into the ventral mesentery during 
the fourth week (16) 
 
3.2.2 Intra hepatic anatomy 
The hepatocytes secrete bile into the bile canaliculi. The bile flows through 
the canaliculi toward the center of the hepatic cords and drains into hepatic 
ductules which coalesce and drain into successively larger ducts in segmental 
pattern. The bile ducts draining each segment are considered third-order 
ducts. The sectoral bile ducts are second-order ducts with the main right and 
left ducts referred to as the first-order ducts (17). The hepatic ducts course 
along the portal vein and hepatic artery branches, which together constitute 
the portal triad. 
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3.2.3 Extra hepatic anatomy 
The left and right hepatic ducts merge to form the common hepatic duct 
(CHD). The bile duct confluence is located in the hilar plate anterior to the 
portal vein. A sheath covers the bile duct and hepatic artery branches, which 
is continuous with the hepatoduodenal ligament in the extra hepatic region. 
There are many variations in the confluence pattern during the formation of 
the common hepatic duct. 
 
 
Fig.2 : Anatomy of liver, biliary system, duodenum and pancreas (18) 
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3.2.4. Common bile duct 
The cystic duct from the gallbladder drains into the common hepatic duct to 
form the common bile duct (CBD). The CBD is situated anterior to the portal 
vein along the right edge of the lesser omentum. It courses caudad behind the 
first portion of the duodenum then runs in an oblique fashion on the dorsal 
aspect of the pancreas in the pancreatic groove.  
 
Fig.3 : Gallbladder and Extrahepatic bile ducts (19) 
Most of the time, the CBD in the pancreatic groove is covered by pancreatic 
tissue or embedded within pancreatic tissue and in 12% of cases it has a 
posterior bare area (20). CBD usually joins the pancreatic duct (70%) and 
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they enter the second portion of the duodenum on its posteromedial wall at 
the major papilla (21). 
The union of the CBD and the major pancreatic duct creates the ampulla of 
Vater. A sheath of circular smooth muscle fibres surrounds the ampulla and 
the intraduodenal portion of the CBD and the major pancreatic duct and is 
known as the sphincter of Oddi (22). In some cases, the pancreatic duct and 
the CBD do not join and each enters the duodenum separately on the 
duodenal papilla.  
The site of entrance of the CBD into the duodenum has been studied by 
several groups and it was found that the CBD enters the descending portion 
of the duodenum in greater than 80% of the cases. Other sites of entrance of 
the CBD are the transverse duodenum and at the angle created by the junction 
between the descending and transverse duodenum (22). 
Tab.1 : The varying diameter of CBD (20)  
 External diameter (mean) Internal diameter (mean) 
Suprapancreatic CBD    5 – 13 mm (9 mm)   4 – 12 mm (8 mm)  
CBD near duodenal papilla    constant   1.5 – 7.5 mm (4 mm) 
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There are several anatomic variations in which sectoral ducts may enter the 
CBD directly. These variations are uncommon but may be the cause for 
morbidity during biliary operation. 
3.2.5. Blood supply 
The extrahepatic bile ducts receive their arterial blood supply from several 
different major arteries. Northover and Terblanche (23) conducted a resin 
cast study in human cadavers in which they described two major axial vessels 
that ran along the lateral borders of the supraduodenal CBD. They named 
these the 3 o'clock and 9 o'clock arteries.  
They reported an average of 8 small arteries with a diameter of 0.3 mm 
supplying the supraduodenal CBD. These arteries arise from below (posterior 
or anterior superior pancreaticoduodenal artery, gastroduodenal artery, 
retroportal artery) and above (right hepatic artery, cystic artery, left hepatic 
artery). In rare cases, there is nonaxial supply from the common hepatic 
artery (23). 
The hilar ducts receive numerous arterial branches from the right and left 
hepatic arteries. These form a rich network around the ducts and are in 
continuity with the plexus around the CBD. In some cases, the 3 o'clock and 
9 o'clock arteries may supply the hilar ducts. The retropancreatic portion of 
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the CBD is usually supplied by multiple small branches from the posterior 
superior pancreaticoduodenal artery.  
Gunji and colleagues (24) used cadaver dissection and corrosion casts to 
describe a communicating arcade between the right and left hepatic arteries. 
They identified small branches from the communicating arcade that supplied 
the hilar bile ducts. At the time of biliary surgery, attention to the 
preservation of the blood supply to the bile ducts is imperative in the 
assurance of anastomotic integrity and the prevention of strictures. 
A fine venous plexus that drains into marginal veins surrounds the surfaces of 
the extrahepatic and intrahepatic bile ducts (25). The marginal veins run in 
the 3 o'clock and 9 o'clock positions similar to the arterial vessels. Inferiorly, 
the marginal veins drain into the pancreaticoduodenal venous plexus. 
Superiorly, the marginal vessels have been shown to enter the hepatic 
substance or join the hilar venous plexus, which eventually drains into 
branches of the portal vein (26).The intrahepatic bile duct venous plexus 
drains into the adjacent portal vein. The veins of the gallbladder do not 
follow arterial branches and have direct drainage into the liver (27). 
Due to the variability in anatomy and its complexity a preoperative 
assessment of the biliary and vascular anatomy by CT arteriography, 
venography, and cholangiography is of significant benefit during complex 
liver and biliary surgery. 
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3.3.0. Pathophysiology  
The gallstones are classified into cholesterol stones and pigment stones 
according to the composition. Each type has a unique epidemiologic, 
structural, and risk factor profile. The framework contain poorly soluble 
component of bile that is precipitated on a three-dimensional matrix of mucin 
and proteins.  
It is formed by cholesterol, calcium bilirubinates, and calcium salts of 
carbonate, phosphate or palmitate. The matrix is composed of large, 
polymeric mucin glycoproteins and small polypeptides (28). 
Gallstones usually take many years to form and the estimated growth rate 
was found to be approximately 2mm per year (29) . 
3.3.1. Cholesterol stones 
These are the commonest stones that account for 80% to 90% of the 
gallstones in the developing world (30). They are usually composed purely of 
cholesterol or have cholesterol as their major constituent.  
Cholesterol is usually soluble in the form of mixed micelles with an optimal 
concentration of bile salts and phospholipids. As bile becomes supersaturated 
due to disproportionate concentrations of the bile salts and fatty acid, the 
excess of cholesterol precipitates. These get embedded in the mucin gel with 
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bilirubinate to form biliary sludge. This eventually aggregates into a gallstone 
(31).  
The chemical composition includes cholesterol monohydrate crystals, 
calcium salts, bile pigments, proteins and fatty acid. These are yellowish 
white in colour and can be as large as 4.5cms. Microscopically, they appear 
as thin, long crystals that are held together by a matrix of mucin 
glycoproteins. These gallstones are typically found in sterile environment. 
3.3.2. Pigment stones 
These stones contribute to about 20% of all gallstones and the percentage is 
much higher in Asian population. The excessive amount of unconjugated 
bilirubin becomes an important factor in the pathogenesis of pigment 
gallstone.  
Bilirubin is the breakdown product of destroyed erythrocytes. It is conjugated 
in the liver with glucuronic acid producing diglucuronides (75% to 80%) and 
monoglucuronides (20%), which are secreted into bile as they are water 
soluble. About 3% of the bilirubin that reaches the liver is hydrolysed by β-
glucuronidases and becomes unconjugated. These along with its calcium salts 
are poorly soluble in water. The levels in normal individual is not sufficient 
to promote stone formation, but in abnormal states the excessive amount of 
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unconjugated bilirubin becomes an important factor in the pathogenesis of 
pigment stones (28).  
Black pigment stones contain predominantly calcium bilirubinate, but can 
also contain calcium carbonate and calcium phosphate in polymer-like 
complexes with mucin glycoproteins. They are formed in bacterially sterile 
environment. They are found in individuals with chronic haemolytic states 
like sickle cell disease and hereditary spherocytosis. They are also common 
in individuals with liver cirrhosis (32), Gilbert syndrome, cystic fibrosis and 
patients who have ideal disease like Cohn’s disease (33) or post ideal 
resections. 
Brown pigment stones are composed of calcium salts of unconjugated 
bilirubin along with varying amounts of cholesterol and protein. They are 
primarily in the bile duct as a result of bacterial infection that releases β-
glucuronidases to hydrolyse glucuronic acid from bilirubin. The most 
common bacteria found are Escherichia coli, Bacteroides, and Clostridium. 
The stasis in the bile ducts and chronic anaerobic infection of bile promotes 
the accumulation of mucin and bacterial cytoskeletons in the bile ducts (34). 
Further ductal obstruction promotes more stasis and bacterial infection, thus 
perpetuating the cycle. Certain parasitic infections like Opisthorchis veverrini 
and Clonorchis sinensis lead to pigment stone formation, where the worm or 
egg directly stimulates stone formation. The calcified overcoat of the parasite 
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egg may serve as a nidus and enhance the precipitation of calcium 
bilirubinate (35).  
Tab.2 : Characteristics of gallstones (36) 
  
Cholesterol 
 
Brown-pigment stone 
 
Black-pigment stone 
 
Origin 
 
Gallbladder   
(secondary stones) 
 
Ducts ± gallbladder 
(primary stones) 
 
Gallbladder ± ducts 
(primary stones) 
 
Component 
 
 
 
 
Predisposing 
factors 
 
 
 
 
 
 
 
 
40–70% cholesterol 
 
 
 
 
- Obesity 
- Bile duct pool 
-Cholesterol synthesis 
-Progesterone 
 
 
 
 
 
 
15% cholesterol 
60% calcium bilirubinate 
15% calcium phosphate 
 
 
- Diet: low protein, 
high carbohydrate 
- Cholangitis 
- Biliary stricture 
- Biliary infection: 
Bacterial or parasitic 
- Biliary stasis: total  
parenteral nutrition, 
vagotomy 
 
2% cholesterol 
6% calcium carbonate 
40% calcium bilirubinate 
9% calcium phosphate 
 
- Cirrhosis 
- Chronic hemolysis 
- Sickle cell anaemia 
- Heart valve replacement 
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Cholesterol 
 
Brown-pigment stone 
 
Black-pigment stone 
    
Shape, size, 
number 
 
 
 
Physical 
characteristics 
Multiple: smooth 
faceted 
Single: smooth, round 
≥2.5cms 
 
Hard, laminated 
Smooth, round 
  
 
1-3cms 
 
Hard 
Multiple, irregular or 
smooth 
 
<0.5cms 
 
Soft, friable 
 
 
3.4.0. Risk factors 
The risk factors for gallstones can be broadly divided into modifiable and 
non-modifiable. The environmental factors and genetic predisposition play an 
interactive role in the formation of gall stones. The inflammatory immune 
response by the individual also plays a role in the susceptibility to stone 
formation (37). 
The role of genes in the formation of gall stones is more evident as there is a 
difference in prevalence with geographic and ethnic variations. There is 
increase in incidence of gallstones in families and identical twins of patient 
with gallstones (3).   
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Tab.3 : Factors attributing to the formation of gallstones (38) 
Modifiable factors Non-modifiable factors 
  
Pregnancy and parity Increasing age 
Obesity Female gender 
Low-fibre, high-calorie diet Ethnicity 
Prolonged fasting Genetics, family history 
Drugs: clofibrate, ceftriaxone  
Oral contraceptives  
Low-level physical activities  
Rapid weight loss (> 1.5 kg/week)  
Hypertriglyceridemia or 
low high-density lipoprotein 
 
Metabolic syndrome  
Gallbladder stasis  
Specific diseases (i.e. Cirrhosis, 
Crohn’s disease with severe ileal involvement or resection) 
 
 
 
The genes involved in the transport of biliary lipid and lipid metabolism have 
also been identified (39). Individuals with impaired gallbladder contractility 
are also prone for denovo stones and also recurrent gallstones post therapy. 
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3.5.0. Prevention 
There are few steps which can lower the risk of gallstone formation which 
include moderate physical activity and dietary modification with high fibre 
intake and avoidance of saturated fatty acids (40). 
Prevention of gallbladder sludge in patients receiving prolonged total 
parenteral nutrition was prevented by daily administration of cholecystokinin 
(41). Patients receiving long term somatostatin therapy or having rapid 
weight loss have benefited from oral ursodeoxycholic acid (UDCA), one of 
the secondary bile acids which are metabolic by-products of intestinal 
bacteria, in prevention of gallstones. There is currently insufficient data to 
support UDCA for its use to prevent biliary colic or prevention of 
complications in patients with gallstones awaiting cholecystectomy or unfit 
for operation (42). 
 
3.6.0. Clinical spectrum 
As described earlier the common bile duct stones can be primary bile duct 
stones that originate in the bile duct or secondary bile duct stones that have 
descended from the gallbladder (43). The dominant component in primary 
stone is bilirubin and in secondary stone is cholesterol, so it is important to 
distinguish between them. The primary stone often requires a more complex 
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drainage procedure to prevent recurrence as compared to secondary stones 
(44). 
Patients with common bile duct stones (CBDS) have varied signs and 
symptoms, being asymptomatic to having biliary colic, jaundice, cholangitis 
or pancreatitis (45). The prevalence of asymptomatic CBDS is between 5.2% 
to 12% (10). A most common presentation of common bile duct stones is 
biliary colic. This is described as pain, often situated in the right 
hypochondrium or epigastrium which can last from 30 minutes to several 
hours, with associated symptoms such as nausea and vomiting (45). Other 
presentations include jaundice, caused by increased levels of bilirubin in the 
blood which manifests as yellowish pigmentation of the skin, the conjunctival 
membranes over the sclerae (whites of the eyes), and other mucous 
membranes. Pale stools and dark-coloured urine are the other symptoms 
associated with it (46). 
Other two serious, life-threatening complications of common bile duct stone 
include cholangitis and gallstone pancreatitis. The acute obstructive 
ascending cholangitis is caused by infection of the obstructed biliary ductal 
system. The commonest organism cultured is E.coli and it responds with 
antibiotics in more than 75% of cases (47). The classical symptoms of 
Charcot’s triad which includes right upper quadrant pain, jaundice and fever 
may be encountered. Less common is Reynolds’s pentad which includes 
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shock and altered mental status (44). Despite the advancement in therapy, 
acute ascending cholangitis carries a mortality rate of 10% to 20% (48). 
It is difficult to infer why some patients with gallstones suffer from 
pancreatitis while others are spared of this potentially lethal complication. A 
study using insitu cholangiogram catheter showed spontaneous passage of 
bile duct stone in approximately one third of patients, based on stone 
disappearance six weeks after diagnosis (49). Recent studies show that there 
was increased risk of pancreatitis with small gallstones, excess cholesterol 
crystals, and good gallbladder emptying (50),(51). Small gall stones caused 
more distal obstruction that lead to bile reflux into the pancreatic ducts which 
in turn activated release of pancreatic enzymes into the glandular interstitium 
with duct injury (52). Though majority are self-limiting disease, the mortality 
can go upto 10% (53). The mortality rate remains less than 1% for mild acute 
pancreatitis and can go upto 10% to 30% for severe acute pancreatitis (54). 
Patients with symptomatic bile duct stones if left untreated are at high risk of 
recurrent symptoms and complications. During a follow up period of six 
months to 13 years, a study showed recurrent symptoms in more than one 
half of patients who had retained bile duct stones (55) and 25% of patients 
developed serious complications (45). Therefore specific therapy is indicated 
regardless of the symptoms due to the potential serious complications of bile 
duct stones. 
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3.7.0. Diagnosis 
In the recent era of widely available advanced technology, a clinical approach 
still remains paramount. A clinician should be able to recognise the typical as 
well as atypical presentations. The newer techniques of biliary imaging have 
simplified the diagnosis of bile duct stones, with non-invasive methods 
having lower risk and invasive techniques having greater accuracy. 
3.7.1. Laboratory Tests 
Patients with the above clinical spectrum require further diagnostic laboratory 
investigations to assess for the presence of common bile duct stone. The liver 
function tests (LFT’s) is used as a screening blood investigation for CBDS 
(56). An elevated serum bilirubin and alkaline phosphatase are considered as 
markers of biliary obstruction. But these are neither highly sensitive nor 
specific (57). Elevated alkaline phosphatase and serum gamma glutamyl 
transpeptidase (GGT) were the most frequent abnormalities (upto 90%), 
noted in the laboratory valves by Anciaux et al in patients with symptomatic 
CBDS (58). Elevated serum bilirubin levels is more common during 
complete obstruction of the bile duct (45). There have been case studies by 
Murohisa et al. (59) and Sheen-Chen et al. (60) which reported high level CA 
19-9 in CBDS with cholangitis. There are rare reports which shows profound 
elevation in serum transaminase levels (up to 2000 IU/L), mimicking viral 
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hepatitis, but decline rapidly over several days unlike viral syndromes which 
take a longer duration(61). Laboratory studies therefore must be used in 
addition to imaging modalities to predict the presence of CBDS.  
3.7.2. Imaging Modalities 
Trans abdominal ultrasonography (TUS) is the first line of investigation in 
patient suspected with common bile duct stone (45). The sensitivity and 
specificity for detecting CBDS is between 25% to 63% and  95% respectively 
(62). But the dilation of the common bile duct and the investigators’ 
experience plays an important role.  Barkun et al. predicted CBDS upto 95% 
in patients older than 55 years with abnormal liver enzymes and CBD 
dilation on ultrasonography (63). 
Endoscopic retrograde cholangiopancreatography (ERCP) was 
considered as the gold standard test for the detection of CBDS (45). Earlier  
this was used primarily in diagnosis, but today it’s reserved as a therapeutic 
modality (46). ERCP has sensitivity of 90% to 95% (64),(65) and a 
specificity of 92% to 98% in detecting CBDS (66),(67).  Christensen et al 
showed that this procedure was associated with a morbidity and mortality rate 
of 15.9% and  1% respectively (68). 
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Endoscopic Ultrasound (EUS) involves insertion of an endoscopic 
ultrasound probe through the stomach and up to the second half of the 
duodenum for imaging CBD. This would have the advantage of not having 
the  interference  from the  subcutaneous fat  or  that from  bowel gas (69).  
The sensitivity is about 95%, and the specificity was between 95% to 98% 
(70). This was more sensitive than trans abdominal ultrasound and its 
sensitivity is compared to that of diagnostic ERCP. This procedure had less 
morbidity as compared to ERCP, which was a major advantage (46). EUS is 
a relatively non-invasive test with excellent sensitivity and specificity for 
diagnosing CBD stones, but it is highly examiner dependent.  
Magnetic Resonance Cholangiopancreatography (MRCP) has emerged as 
an accurate, non-invasive diagnostic modality for evaluating the biliary ducts 
(71). It was helpful in identifying patients who would benefit from early 
intervention (72),(73). A recent meta-analysis showed that MRCP had an 
excellent overall sensitivity of 95% and a specificity of 97% in diagnosing 
the level and presence of biliary obstruction (74). EUS and MRCP had 
similar detection rate of CBDS (75). The major disadvantages of MRCP were 
unit availability, the lower spatial resolution (76), potential claustrophobia, 
and the inability to evaluate patients with ferromagnetic implants or  
pacemakers (77).  
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Intraoperative Cholangiography (IOC) is the technique where the cystic 
duct is catheterised and radio-opaque dye is injected to study the biliary 
anatomy. The routine use of IOC is still controversial, there are groups 
favouring and others advocating only a selective use and while others report 
no advantage with respect to missed CBDS (78),(79),(80). However it is 
found to be an useful tool to identify CBDS (57). This is performed during 
laparoscopic or open cholecystectomy. The sensitivity of IOC was 98% and 
specificity was 94% in detection of common bile duct stones (81). The 
various causes for failure of IOC include inability to cannulate the cystic 
duct, air bubbles mimicking stones, leakage of contrast fluid during the 
injection , spasm of the sphincter of Oddi and failure to fill the biliary tree 
because of too rapid contrast flow. Supporters of this procedure claim that 
this ensures fewer retained stones, reduction in common bile duct injuries and 
postoperative ERCPs (82),(83). This procedure adds about 15 minutes to the 
overall operating time (84). 
Conventional Computed Tomography (CT) is the other modality available 
with a sensitivity of 87% and a specificity of 97% for the diagnosis of CBDS 
(85),(86).  Kondo et al. found that CT scanning was equivalent to MRCP, but 
had the risk of allergic reaction to contrast used (87). 
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Intraductal Ultrasonography (IDUS) has been useful in identifying 
residual small stones after endoscopic lithotripsy or when ERCP is not 
diagnostic. Though IDUS is found to increase the sensitivity and specificity 
in the diagnosis of CBDS, there is notable increase in procedure time of 
about 7 to 15 minutes (88).  
Percutaneous Transhepatic Cholangiography (PTC) is the modality of 
choice in patients with previous gastric operation, distal impacted stones, 
failed ERCP, intrahepatic stones or in patients with cholangiohepatitis.  
Choledochoscopy are miniature endoscopes that can be introduced into the 
bile duct through the duodenoscope during ERCP or IOC. These help in 
nonsurgical management of difficult biliary stones. The direct visualization 
of the biliary epithelium provides additional data in the assessment of biliary 
strictures, targeted tissue acquisition, targeted therapy, and wire guidance 
(89). Therefore Choledochoscopy has a dual purpose in diagnosis as well as 
therapy.  Intraoperative cholangiography had better outcomes regarding stone 
clearance when it is assisted by Choledochoscopy. Both open and 
laparoscopic Choledochoscopy had no difference in stone clearance rate.  
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Tab.4 : Characteristics of the imaging studies for diagnosis of common 
bile duct stones (38)  
Characteristics TUS CT MRCP EUS ERCP 
Sensitivity (%) 
 
 
Specificity (%) 
 
 
Advantages 
 
 
 
 
 
 
 
 
 
25-63 
 
 
95-100 
 
 
Inexpensive, 
Safe,  
Widely 
available, 
Portable 
 
 
 
 
 
 
71-75 
 
 
97 
 
 
Detection of 
concomitant 
intrahepatic 
duct stones, 
liver 
parenchymal 
lesions, and 
pancreatic 
lesions 
 
 
85 
 
 
93 
 
 
High accuracy 
for duct stone 
detection, 
Non-invasive 
intrahepatic 
and 
extrahepatic 
duct evaluation 
 
 
 
93-98 
 
 
97-100 
 
 
High accuracy 
for duct stone 
detection, 
Less invasive 
than ERCP, 
Detects small 
stones in a 
non-dilated 
duct 
 
 
90-97 
 
 
95-100 
 
 
High accuracy, 
Therapeutic 
potential 
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Characteristics TUS CT MRCP EUS ERCP 
Disadvantages 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low 
sensitivity, 
Operator 
dependent 
 
 
 
 
 
 
 
 
 
 
 
 
Radiation 
exposure, 
Contrast 
allergy, 
Renal 
impairment 
 
Expensive, 
Time 
consuming, 
Limited value 
in stones         
< 6 mm, 
impacted stone 
at the ampulla 
and dilated bile 
duct >10 mm, 
Claustrophobia 
Ferromagnetic 
implant, 
Artefact 
interference 
 
 
Operator 
dependent, 
High cost of 
equipment, 
Insensitive for 
proximal 
common 
hepatic duct / 
intrahepatic 
duct stones 
 
Higher risk 
than EUS, 
False positives 
(air bubbles), 
False negatives 
with small 
stones in 
dilated duct, 
Unsuccessful 
cannulation 
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3.8.0. Treatment 
Patients with CBDS often times present with complications like cholangitis 
or gallstone pancreatitis are acutely ill. They will require aggressive 
hydration and antibiotic therapy (46).  E.coli and Klebsiella species are the 
commonly detected gram negative bacteria in the bile culture. In recent 
decades there has been polymicrobial cultures due to wide spread use of 
antibiotics and increased instrumentation (52). Patient characteristics and 
regional antibiotic sensitivity patterns govern the choice of antibiotics. The 
first line of treatment is a combination of an aminoglycoside with 
amoxicillin-clavulanic acid (52). If there are contraindications for 
aminoglycosides, then broad spectrum penicillin is a reasonable alternative. 
The therapeutic management of CBDS is based on the local availability of 
expertise. The two broad management of CBDS are pre or postoperative 
ERCP with endoscopic biliary sphincterotomy (EST) proceed later with 
cholecystectomy and the other is a single stage procedure of surgical bile 
duct clearance and cholecystectomy. Many studies had revealed the similar 
effectiveness of both methods of treatment (90),(91). Kharbutli et al. showed 
one-stage management had less morbidity and mortality (7% and 0.19%) than 
a two-stage management (13.5% and 0.5%) (92). 
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There are other modalities of treatment such as electrohydraulic lithotripsy 
(EHL), extracorporeal shockwave lithotripsy (ESWL), laser lithotripsy and 
dissolving solutions which are indicated only in special situations.  
3.8.1. Preoperative Endoscopic Management 
In recent decades, ERCP/EST had gained more acceptance in clearing CBDS. 
The success rate of an isolated ERCP treatment was up to 87% to 97% and 
two or more ERCP treatment was needed in 25% of the patients (93). The 
morbidity associated with this procedure was 5% to 11% and mortality rates 
of 0.7% to 1.2% (94),(95). The various complications included bleeding, 
duodenal perforation, cholangitis, pancreatitis, and bile duct injury (96). A 
follow up study showed symptom free period of up to 70 months (97). ERCP 
was not possible in 3% to 10% of all patients (98). ERCP/EST was preferred 
in patients with CBDS presenting with cholangitis, pancreatitis and increased 
age with substantial comorbidity.  
Endoscopic balloon dilation of the papilla is an alternative method to 
sphincteroplasty as it is easier (99) with lower bleeding rate (100) and better 
preservation of the of function to the sphincter of Oddi (101). But many 
randomised trials showed endoscopic balloon dilation had more failure rate 
and higher rate of pancreatitis in comparison EST. Therefore EST is 
preferred in stone extraction unless contraindicated due to coagulopathy 
(102).  
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For patients with retained stone it is important to ensure adequate biliary 
drainage, therefore short term use of biliary stent followed by further 
endoscopy or surgical treatment is advocated (102). Stenting is also 
considered as an alternative in patients over 70 years of age or with 
debilitating disease (103). It is a “bridge” until further definitive treatment for 
CBDS is executed.  
When laparoscopic common bile duct exploration fails or if there are retained 
stones after the operation (2.5%), ERCP is used as a treatment modality 
(104). In selected patients transhepatic therapies can be considered for CBDS 
(57).Those with previous gastric bypass operations where majority of the 
stomach, duodenum and proximal jejunum are bypassed, endoscopic access 
via a gastrostomy or jejunostomy have been described (105). 
3.8.2. Laparoscopic Common Bile Duct Exploration (LCBDE) 
Laparoscopic biliary surgery has become safe and cost effective with 
advancing technology. The successful outcome depends on several factors 
including surgical expertise, the biliary anatomy, the number and size of 
CBD stones and adequate equipment (106). LCBDE has successful stone 
clearance rates ranging from 85% to 95% and associated morbidity of 4% 
to16% and a mortality of 0% to 2% (107). Tai et al. reported 100% clearance 
rate with no recurrence during a follow up period of 16 months with LCBDE 
(96). Therefore it is used in clearing difficult stones and also to manage acute 
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gallstone cholangitis (108). The complications of this procedure include CBD 
laceration, bile leak and stricture formation (109). They also had a shorter 
hospital stay and lower hospital costs (110).  
There are two approaches to LCBDE either via the cystic duct or trans-ductal. 
If CBDS are detected at the time of laparoscopic cholecystectomy by IDUS, 
IOC, or other modalities, the best treatment for an undilated bile duct is a 
trans cystic approach for stone clearance. On failing alternate approaches 
such as intraoperative or postoperative ERCP/EST may be done. While for a 
dilated common bile duct this may be treated at the same time by a 
laparoscopic choledochotomy, or open CBDE (111).  
LCBDE Trans-Cystic Approach  
This approach is generally used for small stones in a undilated bile duct (98). 
In this approach 100 to 200mL isotonic sodium chloride solution with 1 to 2 
mg glucagon (for relaxation of Oddi’s sphincter) is used to irrigate and flush 
the stones. 
If unsuccessful, a helical basket can be used under fluoroscopic guidance 
over a guide wire. If this fails, a choledochoscope (≤10 French) should be 
used to remove the stones under direct vision (112). Balloon dilation of the 
cystic duct can be attempted for larger stone, but never dilated larger than the 
internal diameter of CBD (113). Isotonic sodium chloride solution irrigation 
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of CBD is done for better visualization. A cholangiogram or ultrasound is 
done to confirm clearance (112). 
This approach proved to be consistent with the goals of a laparoscopic 
approach with minimal morbidity without a T-tube or a drain and a rapid 
recovery in most cases (114). 
Other novel procedures described are the trans cystic balloon dilatation of the 
sphincter of Oddi and ante grade sphincterotomy. This is done when other 
measures fail to clear the stone. There is risk of developing pancreatitis with 
this method. It is safe to avoid this technique in patients with pre-existing 
pancreatitis, CBD dyskinesia, or sphincter anomalies.  
Recent series show successful trans cystic duct clearance has been described 
in 80% to 98% of patients (107). Infection and pancreatitis have been 
reported in 5% to10% of patients and the mortality rate was 0% to 2%. The 
average hospital stay post procedure was approximately 1–2 days. The main 
advantage is that it avoids choledochotomy (112). 
LCBDE Trans-Ductal Approach 
This approach is preferred for large occluding stones in a large duct, 
intrahepatic stones, or an extremely small or tortuous cystic duct. The various 
approaches include dilation of the distal CBD, balloon catheter or basket or 
choledochoscopic manipulation with or without fluoroscopic guidance (115) 
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as well as IOC. After the stone extraction the ductotomy is usually closed 
either primarily or over an appropriately sized T-tube.  
The T-tube helps in decompression of the duct, ductal imaging in the 
postoperative period and providing an access route for the removal of 
residual CBD stones (114). Usually a longitudinal choledochotomy of over a 
distance of approximately 1 to1.5 cm is preferred. A 14-French latex T-tube 
or larger is closed over using 4-0 monofilament absorbable sutures. Trans 
cystic tubes (C-tube) or ante grade stenting with choledochorrhaphy for CBD 
drainage (116) has also been described.  
The complications of  T-tubes in the postoperative period involve 
bacteraemia, dislodgment, obstruction or fracture of the tube (117). The 
patient is generally discharged 2 to 4 days post procedure. T-tube 
cholangiography is done prior to the removal of the tube by 10 to14 days 
postoperatively. Removal can be delayed as late as 4 to 5 weeks after surgery. 
Retained stones can be removed through the matured tract and is 95% 
successful. If unsuccessful post-operative ERCP may be attempted (112). 
Due to potential complications of T-tube drainage, primary closure of the 
CBD without drainage has been advocated by some authors in open biliary 
tract surgery (118). Studies showed shorter operating time, greater patient 
satisfaction, reduced hospital stay (18.3 days versus 31.5 days) (119), 
reduced expenses, early return to work (12.6 ± 5.1 versus 20.4 ± 13.2 days), 
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reduced postoperative complications (15% versus 27.5%) and biliary 
complications like bile leakage or biliary peritonitis (10% versus 20%) in 
primary closure as compared to T-tube drainage (120).  It was noted that 
laparoscopic trans cystic CBDE is less invasive and was associated with 
lower complication rate, but higher failure rates when compared to trans 
ductal approach (121).  
3.8.3. Open Common Bile Duct Exploration 
Many randomized controlled show superior outcomes for standard open bile 
duct surgery as compared to the endoscopic treatment of CBDS(110).  This is 
used when the laparoscopic and endoscopic methods have failed. Martin et al. 
reported greater success and lower mortality with open surgery than ERCP in 
CBDS (91). 
Choledochoenterostomy or a sphincteroplasty are two options along with 
open common bile duct exploration. The experience of the surgeon usually 
dictates the approach.  
Choledocoenterostomy is done in the setting of dilated CBD (size greater 
than 2cms)  with multiple stones or recurrence with distal obstruction (112). 
This provides drainage with good long-term results. The commonly 
performed technique is a side-to-side choledochoduodenostomy where 
supraduodenal CBD is anastomosed to the duodenum (122). Kocher 
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manoeuvre is performed to expose the distal CBD, and choledochotomy is 
made within 2-3 cm of the lateral border of the duodenum. A hand sewn 
diamond-shaped anastomosis is performed with interrupted absorbable 
sutures. 
“Sump syndrome” is a potential rare complication (1%) caused by food or 
other debris caught in the distal CBD (123), usually managed with 
ERCP/EST (124). 
Sphincteroplasty consists of incising the distal part of the sphincter 
musculature and suturing the ductal mucosa to duodenal mucosa. 
Sphincteroplasty is performed following choledochotomy. A catheter or 
dilator is passed distally after mobilising the duodenum by Kocher 
manoeuvre. Then a duodenotomy is performed at the level of the ampulla. 
Then ampulla is incised sufficiently along the anterosuperior border opposite 
the pancreatic duct opening to remove the impacted calculus (112). 
Other alternative operations include transection choledochoduodenostomy 
where the distal trans pancreatic segment of the bile duct is excluded and an 
end to- side anastomosis of the transected common bile duct with the second 
part of the duodenum is performed. This procedure has an excellent long term 
results (122). Another commonly performed technique is the 
choledochojejunostomy with a roux-en-Y loop. 
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3.8.4. Electrohydraulic Lithotripsy (EHL) 
This technique uses shockwave generated by high voltage to fragment the 
bile duct stones. This is done under cholangioscopic or fluoroscopic guidance 
using a balloon catheter (123). It is indicated in packed multiple stones or an 
impacted single large stone. There is increased risk of damaging the bile duct 
wall if the stone is not targeted under direct sight (124). There is high risk of 
tissue damage and bleeding.  
3.8.5. Extracorporeal Shockwave Lithotripsy (ESWL) 
This technique was first used 1980s following its successful use in 
fragmenting renal calculi (45). This involves percutaneous administration of 
sound waves directed at the liver and bile duct. This is used prior to ERCP to 
fragment large stones and facilitate its removal. Few European studies show 
duct clearance rates of  83% to 90% (125). 
3.8.6. Laser Lithotripsy 
This technique uses amplified light energy at a particular wavelength 
focussed into a single beam (45). This can be performed under direct vision 
or fluoroscopic guidance. Several studies show a success between 64% to 
97% for clearing retained stones (126). 
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3.8.7. Dissolving Solutions 
Several types of solutions are available for dissolving gallstones and CBDS 
which have few toxic side effects and no irritation to the biliary tree. Ideal 
solvent is yet to be discovered. 
 Ursodeoxycholic acid (UDCA) and chenodeoxycholic acid has been shown 
to dissolve cholesterol-containing stones. This is beneficial to the western 
population where the majority of the stones are cholesterol stones. UDCA 
therapy showed prevention of recurrence of gallbladder microlithiasis (127).  
Methyl-Tertbutyl-Ether (MTBE) is excellent cholesterol solvent but it is toxic 
to duodenal mucosa and liver.  
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3.9.0. Recurrent common bile duct stones 
Recurrence of CBD stones after endoscopic stone removal is 4% to 24% 
(128), either from de novo primary stone formation or secondary migration 
from the gallbladder (129). Primary CBDSs are associated with bactobilia 
and delayed bile-duct clearance. Dilated main duct (≥13 mm) and the 
presence of a periampullary diverticulum are common risk factors for 
recurrent stones.  
Endoscopic re-intervention is performed and surgery is reserved for 
intractable cases. Patients prone for stone formation ( low-phospholipid 
associated cholelithiasis) should be identified and preventive medical 
treatment with UDCA can be considered (129). The correctable risk factors 
such as biliary strictures, papillary stenosis, and gallstones in patients who 
have gallbladder in situ should be identified and treated to prevent 
recurrence. 
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Chapter 4 
METHODOLOGY 
Cohort of patients diagnosed with choledocholithiasis who presented to the 
outpatient clinic of Hepatic Pancreatic and Biliary Surgery, General Surgery 
and Gastroenterology departments at Christian Medical College, Vellore 
from July 2008 to June 2012 were included in the study following acceptance 
by the Institutional Review Board. Follow up data was noted for these 
patients from the available clinical record. This retrospective descriptive 
study will obtain information from the records based on a standard performa. 
The details will include clinical symptoms, physical findings, biochemical 
tests and radiological reports. In addition the immediate outcome of the 
different modalities of management, and a one year follow up report of the 
patients will be noted from chart reviews. The inpatient and outpatient 
medical records of each patient were collected by the same person to avoid 
interpersonal variability. 
 
 
 
46 
 
4.1.0. Inclusion criteria  
1. Patients with diagnosis of choledocholithiasis between July 2008 and June 
2012 
2. Patients with a first time diagnosis of choledocholithiasis 
3. Age above 18 years 
4. Treatment naive patients with respect to present attack of 
choledocholithiasis 
 
4.2.0. Exclusion criteria  
1. Other biliary tract diseases 
2. Liver parenchymal disease 
3. Previous biliary tract operations or procedures (except previous        
cholecystectomy, laparoscopic or open) 
4. Suspected carcinoma gallbladder 
 
 
 
47 
 
4.3.0. Confounders 
Patients from lower socioeconomic strata may not be able to afford the more 
expensive diagnostic tests, so this may account for missing data.  
Other factors like assessment of clinical profile by different doctors, non-
availability of all data involved in the investigations and treatment, and 
associated co-morbidities could have led to the change in treatment modality.  
 
4.4.0. Bias 
1. Information bias:  
         From the chart reviews there were missing data. 
2. Observer bias 
Inter-doctor variability in clinical examination. 
3. Treatment bias 
Variability in management between the surgical and medical 
department. 
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4.5.0. Statistical methods  
The various statistical methods used in this study were;  
 
1. Descriptive statistics was done with Mean +/- 2 SD. 
2. Categorical variables were analysed using Chi-square test. 
3. Continuous variables were assessed using two independent variable ‘t’ 
test after checking for normality. 
4. Non normal data was analysed using Mann Whitney U test. 
5. Multivariant analysis was done to predict the pre-operative diagnosis 
using binary logistic regression for biochemical variable. 
6. Two proportion test was used to correlate association. 
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Chapter 5 
RESULTS 
A total number of 500 patients with choledocholithiasis, had presented to    
CMCH, Vellore during the study period July 2008 to June 2012. The 
demographic data of the study group; 
           
Fig.4: Sex ratio 
 
The demographic data showed a male population of 53% and a female 
population of 47%.  
 
0
100
200
300
400
500
Sex
Male
(53%)
Female
(47%)
n = 500 
50 
 
 Tab.5: Distribution of the data studied 
 
The data distribution showed an age distribution ranging from 18 to 89 years 
with a mean age of 52 years.  
 
 
 
 
Study                                        Number           Minimum       Maximum             Mean              Std. Deviation 
Age 500 18 89 52.14 14.161 
BMI 47 16.7 31.1 22.151 3.6717 
S. Bilirubin 489 0.2 40.3 3.193 5.1042 
SGOT 490 11 1126 77.52 99.574 
SGPT 490 5 795 75.01 91.292 
S. Alkaline phosphate 490 37 3281 258.52 260.162 
LDH 57 230 2220 658.54 409.603 
S.Amylase 191 6 19000 768.29 1967.272 
S.Lipase 179 5 33490 1658.59 4558.618 
Total Cholesterol 161 77 511 181.77 56.161 
Triglyceride 162 24 551 168.30 97.289 
S.LDL 162 7 791 109.87 67.074 
Haemoglobin 476 5.1 16.9 11.844 1.9097 
AC 221 53 469 120.19 58.111 
PC 231 70 864 162.84 102.939 
INR 
 
CBD size 
446 
 
269 
0.1 
 
3.7 
3.9 
 
37.0 
1.063 
 
11.558 
0.2560 
 
4.7625 
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Fig.5: Population distribution of the study group 
 
 
 -  Individual person 
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The majority of the population were distributed over the eastern states. The 
states of West Bengal (43%) followed by Tamil Nadu (19%) and Jharkhand 
(14%) constituted the majority of the study population. 
 
Fig.6: The frequency of clinical symptoms during presentation 
 
 
The above graph showed the predominant clinical symptoms at presentation 
were abdominal pain (76%), followed by jaundice (45.4%), and cholangitis 
(25.4%). 
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Fig.7: The frequency of clinical signs during presentation 
 
The above graph showed that majority of the patients did not have any major 
clinical signs at presentation. 
Fig.8: The co-morbidities associated with the patients 
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The majority of the patients (65.6%) did not have any comorbid illness but 
about 29.6% of the population had diabetes, hypertension or both. There was 
a small population with other conditions like Tuberculosis, Sickle cell 
anaemia, Thalassemia, Hereditary spherocytosis and Iron deficiency anaemia.  
 
Fig.9: The personal habits of the patients 
 
 
The above graph showed majority of the patients (87.6%) did not have any 
addictions to alcohol, smoking or tobacco intake. 
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Fig.10: Total bilirubin values 
 
The total bilirubin values were less than 1.9 mg/dL in 63.9% of the study 
population, 13% upto 3.9 mg/dL and only 23.1% had a value above 3.9 
mg/dL.  
 
           Fig.11: SGOT values                         Fig.12: SGPT values 
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The synthetic functions of liver as reflected in SGOT and SGPT were normal 
in majority of the patients. The values were less than 50 U/L in 53.2% and 
54.4% for SGOT and SGPT respectively. 
  
    Fig.13: Alkaline phosphatase             Fig.14: Total cholesterol  
 
 
The serum alkaline phosphatase was elevated in majority of the patients. It 
was elevated  in the  range of 100 to 399 U/L in 54.7% and above 400 U/L in 
only 18.8% of the study population. It was below 100 U/L in 26.5%. The 
total cholesterol was elevated above 160 mg/dL in 65.2%. 
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Fig.15: The parameters screened by Ultrasonography 
   
Fig.16: The common bile duct diameter measured by USG 
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The abdominal ultrasonography was able to screen CBD stones in 63.8% of 
the population screened. It showed IHBRD in 54.3% and gallstones in 44.6% 
of the population. There was only 1.3% of the population with 
pericholecystic collection. 
The abdominal ultrasound was able to measure the CBD size and a majority 
of the study population (58.5%) had a size greater than 10mm. 
 
Fig.17: The parameters screened by CT scan 
  
The CT scan of the abdomen detected dilated CBD in 85.7%, IHBRD in 
77.6% and filling defect in 84.3%. 
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Fig.18: The parameters screened by MRI 
  
The MRI scan detected dilated CBD in 90.3%, IHBRD in 84.4% and filling 
defect in 86.6% of the screened population. 
Fig.19: The primary intervention 
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A vast majority of the study population (96.9%) underwent ERCP as the 
primary modality of treatment and the remaining underwent direct CBD 
exploration as they were suspected to have underlying choledochal cyst or 
hepatolithiasis in addition.  
 Fig.20: Rate of successful clearance of ERCP 
 
ERCP was successful in 63.9% of the study population and the rest had to 
undergo a secondary procedure like CBD exploration or drainage procedure. 
Among those who had successful ERCP clearance, 74.8% had it cleared in 
the first attempt, 19.1% in the second and 6.1% required more than two 
attempts, and some even upto six attempts. Almost all of them had a CBD 
diameter of more than 10mm. 
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Tab.6: Correlation of jaundice and the outcome of ERCP 
 
 
Jaundice 
 
n = 438 
 
 
Successful ERCP                     
n (%) 
 
Failed ERCP 
n (%) 
 
Significance 
 
 
Yes 
 
107 (53.2%) 
 
94 (46.8%) 
 
 
 
P – 0.001 
 
 
 
 
No 
 
171 (72.2%) 
 
66 (27.8%) 
 
The above table shows a significant correlation between the presence of 
jaundice and the failure rate in ERCP. 
Fig.21: Correlation of total bilirubin in patients with jaundice 
 
 
45% 
13% 
42% 
< 1.9 mg/dL
2 to 3.9 mg/dL
> 3.9 mg/dL
n = 201 
62 
 
Fig.22: Correlation of Alkaline phosphatase in patients with jaundice 
 
 
The above pie charts show the biochemical correlation of total bilirubin and 
alkaline phosphatase with jaundice. 
It was noted that a majority of patients with jaundice (42%) had an elevated 
total bilirubin of more than 3.9 mg/dL. 
The alkaline phosphatase value in patients with jaundice ranged from 100 to 
399 U/L in majority of the patients (64%). 
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Tab.7: CBD diameter and its correlation with ERCP outcome 
 
 
ERCP 
 
Total 
number 
 
Mean CBD 
diameter 
 
Standard 
deviation 
 
Standard  error 
Mean 
 
Significance 
 
SUCCESSFUL 
 
143 
 
11.179 
 
4.9722 
 
0.4158 
 
 
p – 0.039 
 
FAILED 
 
100 
 
12.484 
 
4.6009 
 
0.4601 
 
This table shows the significant correlation between the CBD diameter and 
the successful outcome of ERCP. 
Fig.23: Correlation of CBD diameter with Age 
 
The above pie chart shows the correlation between the CBD diameter and the 
age of the patient. There was no significant association noted between the age 
and the CBD diameter in this scenario (p value – 0.8). 
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Fig.24: The number of attempts 
 
Tab.8: The number of attempts and ERCP outcome 
 
 
Number of 
attempts 
 
n = 438 
 
 
Successful ERCP                     
n (%) 
 
Failed ERCP 
n (%) 
 
Significance 
 
 
≤ 2 
 
265 (95.3%) 
 
146 (91.2%) 
 
 
 
P – 0.08 
 
 
 
 
≥ 3 
 
13 (4.7%) 
 
14 (8.8%) 
 
There above table shows a partial significance between more than three 
attempts and failure of ERCP. 
74.8% 
19.1% 
6.1% 
1st attempt
2nd attempt
> 2 attempts
n = 438 
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Tab.9: Cholecystectomies and ERCP outcome 
 
Successful 
ERCP 
Cholecystectomy 
before ERCP 
Laparoscopic 42 (9.6%) 
Open  52 (11.9%) 
Cholecystectomy 
after ERCP 
Laparoscopic  52 (11.9%) 
Open 33 (7.5%) 
 
Failed ERCP CBD exploration / Drainage procedures 
102 (23.3%) 
  
 Lost to follow up 
 
Successful ERCP / Advised 
Laparoscopic Cholecystectomy 
99 (22.6%) 
157 (35.8%) 
Advised CBD Exploration 
 
58 (13.2%) 
 
Total 
438 
 
The above table gives the overall outcome following an ERCP. About 35.8% 
did not undergo cholecystectomy or bile duct exploration after the primary 
intervention.  
There was also a major group (21.5%) which had undergone either open or 
laparoscopic cholecystectomy prior to their presentation with CBD stones.  
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Tab.10: Successful laparoscopic cholecystectomy following ERCP   
 
Successful ERCP proceed 
cholecystectomy 
(n = 85) 
 
Successful Laparoscopic 
cholecystectomy 
52 (61.3%) 
 
Laparoscopic converted 
Open cholecystectomy 
 
30 (35.2%) 
 
Open cholecystectomy 
 
3 (3.5%) 
 
Total 
 
85 
 
The above table shows that almost a third of the patient who underwent 
laparoscopic cholecystectomy following a successful ERCP had to be 
converted to open procedure due to failure to define the Calot’s anatomy and 
due to dense adhesions. 
Fig.25: Secondary intervention 
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Among those who failed primary intervention of ERCP, 98% underwent a 
successful CBD exploration. There were sometimes temporary drainage 
procedures like percutaneous transhepatic biliary drainage (PTBD) 
 done which was followed by a definitive procedure like CBD exploration. 
There was a small number (2%) who had undergone CBD exploration and 
presented with recurrent/residual CBD stones, and required ERCP for CBD 
stones extraction. 
Fig.26: Secondary procedures with open CBD exploration 
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patients), large dilated CBD with impacted stones (4 patients), large 
choledochoduodenal fistula (4 patients), Mirizzi’s syndrome (3 patients) and 
mid CBD stricture (1 patient). 
The reasons for proceeding to choledochoduodenostomy were mainly dilated 
CBD with multiple stones (16 patients) and for choledochojejunostomy were 
large stone with distal obstruction or distal duodenal deformity (4 patients). 
The other procedures which accompanied were sphincteroplasty (2 patients) 
and liver biopsy (2 patients).   
The patients on follow up were studied for the return to normalcy in their 
selective liver function tests and radiological imaging. 
 
Fig.27: Total bilirubin values on follow up 
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There was a drop in the total bilirubin value to normal in most of the patients. 
There were none in the follow up group with a value greater than 3.9 mg/dL. 
Among the 5 patients with a value from 2 to 3.9 mg/dL, (one had undergone 
open CBD exploration and the remaining four had undergone initially an 
ERCP). The one patient, who had the open CBD exploration, was found to 
have non-alcoholic steatohepatitis with cirrhosis and a normal CBD on 
abdominal ultrasound. Among the 4 who had ERCP, one patient was 
suspected to have a stricture and was advised further imaging with 
EUS/MRCT but did not come for further follow up. One patient had recurrent 
stone and underwent ERCP and successful stone extraction. Two of the 
remaining were found to have only indirect hyperbilirubinemia with normal 
CBD on abdominal ultrasound.   
Fig.28: Alkaline phosphatase on follow up 
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The serum alkaline phosphatase also showed similar trends towards normal 
range. Three patients had a value more than 400 U/L, (One of them had 
undergone open CBD exploration and the remaining two had undergone 
ERCP). The patient who had undergone open CBD exploration was found on 
evaluation by MRCT scan to have probably a terminal bile duct growth and 
was advised side viewing scopy but was discharged at request. Among the 
remaining two patients, one of them as described above was advised further 
imaging with EUS/MRCT but did not follow up. The other patient had 
recurrent CBD stone and advised CBD exploration. 
Among the 21 patients with a follow up value ranging from 131 to 399 U/L, 
(12 had undergone open CBD exploration and 9 had undergone ERCP). 13 of 
them (8 following open CBD exploration and 5 following ERCP) had normal 
CBD with no calculi on the abdominal ultrasound, so were advised follow-
up. 
Among the remaining, from the open CBD exploration group (4), one had a 
left hepatic duct stone and underwent open cholangioscopy and extraction of 
left hepatic duct calculus. The remaining three were suspected to have 
stricture, one of whom underwent HIDA scan which showed no hold up, so 
was advised to follow up. The other two were advised redo hepatico-
jejunostomy.  
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Among the remaining 4 patients from the ERCP, two of them had recurrent 
stones and underwent ERCP and stone clearance. One of them was suspected 
to have portal biliopathy as repeat ERCP was normal. The other underwent 
laparoscopic cholecystostomy and was on follow up. 
Fig.29: Follow up Abdominal Ultrasound scan 
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Among the entire population there were two mortalities. Both patients 
succumbed to the septic complications following the procedure done. One of 
them had undergone open CBD exploration and developed bile leak and the 
other patient had undergone ERCP and had acute cholangitis.  
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Chapter 6 
ANALYSIS 
The total number of patients studied was 500. 
There was almost equal distribution of male to female ratio, showing no sex 
predilection for choledocholithiasis, although female gender is a risk factor 
for gallstones. 
The age group of patient ranged from 18 years to 89 years with a mean age of 
52 years, signifying that choledocholithiasis can occur early in life but 
predominantly affects the middle aged. 
The population distribution was predominantly in the eastern states and more 
in the Bengali community. This was also shown earlier in a population based 
study on choledocholithiasis in various Indian population (4).  
The average body mass index in the study population was 22.15, which falls 
in the normal range. 
Among the various clinical presentations, abdominal pain was the 
commonest presenting complaint which was recorded in 76% of the patients. 
Following this was jaundice which was seen in 45.4% of patients. The other 
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symptoms like pruritus, pale coloured stools, dark coloured urine and 
anorexia were recorded in 10% of the study population. 
The complications of choledocholithiasis like ascending cholangitis and 
pancreatitis was recorded 25.4% and 5.4% respectively. This rate was high 
but could be expected due to a referral bias being a tertiary care centre. 
About 30% of the study population was either hypertensive or diabetic or 
both. There were a small number with haemolytic disease like hereditary 
spherocytosis, thalassemia and sickle cell anaemia. Majority of the patient 
had no comorbid illnesses. 
Few of the patients had icterus on general examination but there were no 
significant findings on abdominal examination. 
On blood investigation the commonest abnormality noted in the liver 
function test was an elevated alkaline phosphatase. The serum alkaline 
phosphatase in majority of the patients were elevated, in the range between 
100 U/L to 399 U/L, which was greater than normal. The other parameter 
which was elevated was the total cholesterol, noticed to be above 160 mg/dL 
in 65% among the tested population. There was no significant difference 
noticed in the other laboratory parameters. Yang et al. showed that total 
bilirubin had the highest specificity of 87.5% to predict common bile duct 
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stone. They also concluded that total bilirubin, SGOT, SGPT and alkaline 
phosphatase had high negative predictive value (130).  
The most common radiological finding in trans-abdominal ultrasound was the 
dilated common bile duct. It was noted that 87.3% of patients had a CBD 
diameter more than 7mm and 58.5% had a diameter more than or equal to 
10mm. The age cut off of 60 years did not reveal significant difference in the 
CBD diameter, which suggests the dilatation was independent of age (p value 
– 0.78).   
The CT scan of the abdomen also revealed a dilated CBD in 85.7% of the 
study population followed by filling defect in the common bile duct and 
IHBRD. A similar screening pattern was seen in the MRI study of the 
abdomen. But overall MRI had the highest sensitivity in picking up a CBD 
stone. 
Following the diagnosis of choledocholithiasis, a major group of the study 
population (96.9%) underwent ERCP and clearance of the stone. The failure 
of which, as seen in 36.1% of the patient, had to undergo a temporary 
drainage procedure like percutaneous transhepatic biliary drainage or a 
definitive procedure like CBD exploration (23.3%) and the remaining were 
lost to follow up. There was a small number which underwent primary CBD 
exploration (3.1%) due to already attempted ERCP at another centre or due to 
associated hepatolithiasis. 
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The leading cause for failure among the ERCP group was large stones 
followed by multiple stones. There were also other important factors like 
abnormal anatomy due to deformed duodenum, periampullary diverticulum 
and few due to technical difficulty and uncooperative patient. 
Most times (74.8%) the stone was extracted in the first attempt. When there 
was more than two attempts the chance of failure was borderline significant 
(p value – 0.08). 
Analysis was done to correlate clinical, biochemical and radiological features 
to the successful clearance of the common bile duct stone. 
A two proportions test (Z-test) was done to correlate jaundice and outcome of 
ERCP, and it was found to have a higher failure rate in the presence of 
jaundice (p value – 0.0002). Similarly there were significant failure rates in 
those with cholangitis (p value – 0.002) as compared to those with 
pancreatitis (p value – o.246).   
There was no gender predilection or significant correlation between comorbid 
illnesses and personal addictions to the outcome of ERCP. 
The abdominal ultrasound measurement of the CBD diameter (mean diameter 
– 12.484mm) was found to be significant (p value – 0.039) in the group with 
failed ERCP as compared to those with successful ERCP. 
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The patients who underwent laparoscopic cholecystectomy following a 
successful clearance of CBD stones by ERCP, had a conversion rate of 
around 35.8%. The routine conversion rate was about 5% (131). Morshed et 
al. showed that the conversion rate following an ERCP is 13.3% if performed 
after 72 hours and it increases to 33.3% if after a week (132).  The majority 
of the secondary intervention was by CBD exploration. A small number 
presented with recurrent CBD stones following CBD exploration (3%), who 
underwent ERCP and stone clearance. 
Majority of the study population was lost to follow up and only about 20% 
had regular follow up data. The reason could be that they were well post 
procedure, the long waiting period of 8 to 10 weeks prior to operation or 
could be the geographic distance and difficulty in coming for a follow-up. 
Follow up of the patients showed that the total bilirubin had begun to 
normalise in majority of the patients (95.3%). The abdominal USG revealed 
no stones in CBD except in four patients (5%) who had a recurrent/residual 
stone which was removed by ERCP. The CBD size also was normal except in 
7% who had mildly dilated CBD about 10mm. There were two mortalities 
following septic complications post procedure.  
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Chapter 7 
CONCLUSIONS 
 The most common clinical presentation of choledocholithiasis was 
abdominal pain. 
 Abdominal ultrasonography was an effective initial investigation to 
indicate the presence of choledocholithiasis.  
 MRI was most sensitive to demonstrate CBD stone.  
 ERCP was the preferred primary intervention at this institution. 
 Absence of jaundice was an important predictor for a successful outcome 
of ERCP. 
  More than two attempts at ERCP predicted a higher failure rate in 
complete stone clearance. 
 Common bile duct diameter more than 12.5mm showed a significantly 
higher failure rates in ERCP and stone clearance. 
 Delayed laparoscopic cholecystectomy following ERCP could lead to a 
higher conversion rate. 
 Common bile duct exploration was the preferred intervention following 
failure of primary intervention. 
 Alkaline phosphatase was a better predictor of outcome on follow up. 
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Chapter 8 
LIMITATIONS  
 The data quality relies on accuracy of written record or recall of 
individuals also termed as recall bias. 
 All the important data was not available and the missing data had to be 
excluded, reducing the strength of this study. 
 The financial constraints played an important role in the management 
of the patients. 
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Chapter 10 
ANNEXURES 
9.1.0. Performa 
Name:        Serial No: 
Hospital No:        Married: 
Age:        Place: 
Sex:        BMI: 
Clinical symptoms:  
1. History of cholangitis (present / absent)  
2. Acute pancreatitis (present / absent) 
3. Dark urine (present / absent) 
4. Pale colored stools (present / absent) 
5. Pruritus (present / absent) 
Clinical signs:   
1. Icterus (present / absent) 
2. Abdominal tenderness (present / absent)  
3. Palpable gall bladder (present / absent) 
Biochemical findings: 
1. Serum Bilirubin   <1.9,   2.0 – 3.9,    and     >4.0 
2. Serum Alkaline phosphatase   < 100,   100 - 399,  >400 
3. Liver enzymes (SGOT/SGPT)     < 50    and    >50 
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Radiological findings: 
USG    Presence of choledocholithiasis (present / absent)    
Size of common bile duct 5mm or less, 6mm, 7mm, 8mm, 9mm, 10mm or more 
            Presence of intrahepatic biliary dilatation (present / absent) 
            Presence of cholelithiasis (present / absent) 
CT scan   Bile duct dilatation (present / absent)   
     Presence of filling defects in Common bile duct (present / absent)   
                 Cholelithiasis (present / absent) 
MRI Scan  Bile duct dilatation (present / absent)   
                   Presence of filling defects in Common bile duct (present / absent)   
                   Cholelithiasis (present / absent) 
Endoscopic ultrasound  Bile duct dilatation (present / absent)   
    Presence of filling defects in Common bile duct (present / absent)   
                                        Cholelithiasis (present / absent) 
Treatment: Primary treatment  ERCP/ common bile duct exploration 
Failure of pre-treatment - abnormal anatomy (Y/N),   large size stone (Y/N), 
multiple  stones (Y/N), Others  
Follow up:  Serum Bilirubin   <1.9,   2.0 – 3.9,  and   >4.0 
                    Serum Alkaline phosphatase < 100,  100 - 399,   >400 
                    Liver enzymes (SGOT/SGPT)   < 50  and >50 
 
 
